However, the migration and engraftment of tumor cells with PARP-1 inhibitor pretreatment didn’t significantly altered in vivo or in vitro, suggesting that PARP-1 inhibition is an important protector of HCC recurrence after IR by preventing the formation of susceptible hepatic milieus rather than decreasing the degree of malignant in HCC. The gene discussed is PARP1; the disease is hepatocellular carcinoma.